Encompass Health Corporation (NYSE:EHC) Receives $143.86 Average PT from Brokerages

Shares of Encompass Health Corporation (NYSE:EHC) have received a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $143.8571.

A number of equities research analysts have commented on EHC shares. Barclays reduced their price objective on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a report on Tuesday, May 5th. Leerink Partners set a $152.00 price target on Encompass Health in a report on Friday, May 22nd. Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings cut shares of Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, June 26th. Finally, TD Cowen assumed coverage on Encompass Health in a research report on Thursday, May 28th. They set a “buy” rating and a $125.00 target price on the stock.

Encompass Health Price Performance

EHC stock opened at $110.17 on Friday. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $10.93 billion, a PE ratio of 18.39, a P/E/G ratio of 2.41 and a beta of 0.74. The business’s fifty day moving average price is $103.56 and its 200 day moving average price is $103.43. Encompass Health has a 12-month low of $92.77 and a 12-month high of $127.99.

Encompass Health (NYSE:EHC) last released its earnings results on Thursday, April 30th. The company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.51 by $0.09. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.37 EPS. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. On average, sell-side analysts anticipate that Encompass Health will post 5.97 EPS for the current year.

Encompass Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Wednesday, July 1st will be issued a dividend of $0.19 per share. The ex-dividend date of this dividend is Wednesday, July 1st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s dividend payout ratio (DPR) is currently 12.69%.

Insider Buying and Selling

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $104.56, for a total transaction of $71,309.92. Following the completion of the sale, the executive vice president directly owned 24,755 shares of the company’s stock, valued at approximately $2,588,382.80. This trade represents a 2.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Encompass Health

Institutional investors have recently bought and sold shares of the company. EP Wealth Advisors LLC lifted its stake in shares of Encompass Health by 2.4% in the 2nd quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock worth $453,000 after acquiring an additional 88 shares during the period. Allworth Financial LP increased its stake in shares of Encompass Health by 14.7% during the third quarter. Allworth Financial LP now owns 701 shares of the company’s stock worth $89,000 after acquiring an additional 90 shares during the period. Gamco Investors INC. ET AL raised its holdings in Encompass Health by 2.0% during the first quarter. Gamco Investors INC. ET AL now owns 4,813 shares of the company’s stock worth $466,000 after purchasing an additional 94 shares in the last quarter. Gibson Capital LLC boosted its holdings in Encompass Health by 4.3% in the 1st quarter. Gibson Capital LLC now owns 2,431 shares of the company’s stock valued at $235,000 after purchasing an additional 101 shares in the last quarter. Finally, Leuthold Group LLC increased its position in Encompass Health by 0.3% during the 4th quarter. Leuthold Group LLC now owns 31,168 shares of the company’s stock worth $3,308,000 after purchasing an additional 104 shares during the period. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.